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diabetes patients increased substantially in the past two decades. Future studies 
may consider the impact of these increases on adherence and long-term outcomes.
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The imPacT of meDicare ParT D on DiaBeTes Drug use anD 
exPenDiTures
Bonakdar Tehrani A.
Virginia Commonwealth University, Richmond, VA, USA
Objectives: To determine the extent to which Medicare Part D affect diabetes drug 
use and expenditures among different racial groups in the United States. MethOds: 
The Medical Expenditure Panel Survey data files from 2001 to 2010 were used to 
examine changes in diabetes drug use and out-of-pocket expenditures after Part D 
implementation. I employ Difference-in-Difference (DD) methodology to compare 
racial differences in diabetes drug use and expenditures before and after 2006 for 
diabetic seniors who are covered by Part D. In other words, I compare people 65 years 
of age and older before and after Medicare Part D implementation to find the extent 
to which average diabetes drug use and expenditures have changed. Results: The 
results demonstrate that after Part D implementation diabetes drug expenditures 
significantly decreased for all senior participants on average by $199, and aver-
age diabetes drugs filled during the year increased by 0.2 but was not significant. 
Although the results show that overall diabetes drug expenditures significantly 
decreased for minorities by $159, DD estimates show that Part D increases diabetes 
drug expenditures and decreases average diabetes drug use among minorities 65 
years of age and older compared to whites by $42. cOnclusiOns: The findings 
demonstrate that Medicare Part D significantly reduces out-of-pocket expenditures 
and increases diabetes drug use, however, African-Americans and Hispanics do not 
benefit from this reduction. In other words, Part D did not reduce racial disparities 
in diabetes drug expenditures. Additionally, Part D did not have any significant 
effect on diabetes drug use.
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clinical anD DemograPhic characTerisTics of PeoPle wiTh TyPe 2 
DiaBeTes melliTus (T2Dm) iniTiaTing canagliflozin from a uniTeD 
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Objectives: Canagliflozin (CANA) is the first sodium glucose co-transporter 2 
inhibitor to be approved to treat adults with T2DM in the US. This study describes 
the early prescription pattern of patients receiving CANA in routine clinical practice. 
Clinical and demographic characteristics as well as treatment history are sum-
marized. MethOds: This retrospective cohort study used data from a large US 
health plan for commercial and Medicare Advantage enrollees with T2DM filling a 
prescription for CANA between market entry on April 1 and June 30, 2013. Analysis 
included demographics, first observed dosage, prescribing specialty, antihypergly-
cemic agents (AHAs) preceding a CANA prescription, and A1C level proximal to 
initiation, where available. The diabetes complications severity index (DCSI) was 
used to capture baseline health status. Results: In this sample of patients receiv-
ing CANA (n= 1088), 44% were female, geographically skewing toward the South 
(62%). The average age was 56 years. Approximately 48%, 30%, 5% of CANA pre-
scriptions could be attributed to primary care physicians, endocrinologists, and 
other specialties, respectively, with the remainder unknown. The most common 
CANA dose was 100mg (71%). The mean (SD) number of other T2DM drug classes 
at baseline was 1.66(1.10) with oral AHA (41%) and GLP-1 (17%) being the most 
common pre-treatment monotherapies and oral AHA or GLP-1 plus insulin (31%) 
the most common pre-treatment dual therapy. For patients with available lab data 
(N= 350), 32% had baseline A1C > 9%, 38% had 7.5 to ≤ 9%, 20% had 6.5 to < 7.5%, 
and 10% had < 6.5%. The mean (SD) DCSI was 0.75(1.11); 56% had a zero DCSI value 
at baseline. cOnclusiOns: This study characterizes patients treated in routine 
clinical practice immediately after CANA became available in the US. This early 
prescription pattern indicates CANA was prescribed by primary care physicians 
and endocrinologists across a range of A1C levels and following a variety of AHAs.
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recePTor agonisT TheraPy in TyPe 2 DiaBeTes melliTus
Johnston S.S.1, Nguyen H.2, Felber E.2, Cappell K.1, Nelson J.1, Chu B.C.3, Kalsekar I.2
1Truven Health Analytics, Bethesda, MD, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 
3Truven Health Analytics, Santa Barbara, CA, USA
Objectives: To compare medication use and treatment patterns of glucagon-like 
peptide-1 receptor agonists (GLP-1RAs) among type 2 diabetes mellitus (T2DM) 
patients newly initiating exenatide once weekly (exenatide QW), exenatide twice 
daily (exenatide), or liraglutide. MethOds: This administrative claims-based retro-
spective cohort study included patients if they had T2DM, were GLP-1RA-naïve, initi-
ated a GLP-1RA between 2/1/2012-1/31/2013 (initiation date= index), were aged ≥ 18 
years, and had continuous enrollment for 12 months before (baseline) to 6 months 
after index (follow-up). Outcomes included index GLP-1RA adherence (proportion 
of follow-up days covered, dichotomized at ≥ 90% vs. < 90%) and non-persistence 
(switch to non-index GLP-1RA or gap ≥ 60 days in index GLP-1RA during follow-
up). Multivariable regressions (logistic for adherence, Cox proportional hazards for 
persistence) compared outcomes among index GLP-1RAs, adjusting for potential 
confounders. Pre-specified sensitivity analyses were performed stratifying by lira-
glutide 1.2mg and liraglutide 1.8mg and among patients with ≥ 60 days’ supply 
of their index GLP-1RA within ≤ 67 days after index (initial adherers). Results: 
Samples included 4,041 exenatide QW, 4,586 exenatide, and 14,211 liraglutide 
patients. Compared with other GLP-1RAs, exenatide QW had significantly higher 
multivariable-adjusted odd ratios of index GLP-1RA adherence in all analyses (rang-
ing from 0.299 [p< 0.001] for exenatide vs. exenatide QW among initial adherers 
to 0.693 [p< 0.001] for liraglutide 1.2mg vs. exenatide QW among initial adherers).
The multivariable-adjusted hazard ratios of index GLP-1RA non-persistence var-
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Objectives: To compare units per day per claim (units) and costs per day per claim 
(costs) of comparable insulin products by Eli Lilly and Company (LLY) and Novo 
Nordisk (NN), adjusting for baseline patient differences, in state Medicaid claims 
data. MethOds: Claims for comparable LLY or NN insulin for patients with con-
tinuous coverage for ≥ 6 months before their first observed insulin claim (base-
line) were identified from Missouri (MO: 1/1/2011-3/31/2012) and New Jersey (NJ: 
1/1/2011-3/31/2013) de-identified Medicaid claims data. Units were calculated by 
multiplying total quantity per claim (in mL) by strength (1 mL= 100 units) and divid-
ing by total days supplied. Costs were calculated (for patients aged < 65 years only, 
because drug costs for those aged ≥ 65 years are often covered by Medicare rather 
than Medicaid) by dividing the cost of a claim to insurers by total days supplied. 
Regression-adjusted units and costs were estimated using generalized estimating 
equation models, accounting for baseline demographics, select comorbidities, and 
antidiabetic medication use. Results: Claims for 23,325 MO and 9,749 NJ Medicaid 
patients were analyzed. Compared with NN insulin users, LLY insulin users were 
significantly younger, had lower rates of comorbidities, and higher rate of baseline 
insulin use. The regression-adjusted units for all comparable LLY and NN insulins 
were similar, with the exception of significantly lower units for insulin lispro (MO 
only: 67.6 vs. 73.2, P= 0.0009) and LLY human insulin regular vials (MO: 65.4 vs. 
78.3, P< 0.0001; NJ: 45.3 vs. 50.3, P= 0.0365). The regression-adjusted overall cost was 
significantly lower for comparable LLY vs. NN insulin (MO: $5.7 vs. $6.1, P= 0.0046; 
NJ: $4.6 vs. $5.5, P< 0.0001). cOnclusiOns: In both MO and NJ Medicaid, the units 
of comparable LLY and NN insulins in years evaluated were similar for patients 
with similar characteristics; however, the overall cost was significantly lower for 
comparable LLY vs. NN insulin.
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Objectives: In Qatar, over 20% of the population has diabetes. While this is consid-
erable and is associated with a high consumption of antidiabetic drugs, there does 
not seem to be any published reports discussing the utilization and expenditure 
of antidiabetics in Qatar. This project sought to assess the trends of utilization and 
expenditure of antidiabetic drugs at Hamad Medical Corporation (HMC), the major 
health provider in Qatar, over time. MethOds: The study was from the HMC per-
spective, retrospectively obtaining antidiabetics utilization and expenditure data 
from HMC drug utilization database (2007-2012). Defined Daily Doses were used as 
the utilization unit. Data were organized according to drug, drug concentration, drug 
class, hospital, and year. Descriptive statistics were used to illustrate distributions of 
variables, and cross-tabulation was used to provide comparison of frequency data, 
used to generate data tables and charts as appropriate. Results: The utilization 
and expenditure of antidiabetic drugs increased over time. The increase in utiliza-
tion seems to have been consistent with the increase in population. The expenditure 
trend however, is considerably higher. Sulfonylurea and biguanide drug classes were 
utilized the most, whereas Dipeptidylpeptidase-inhibitors were associated with the 
highest expenditure. Out of eight hospitals in HMC, Hamad General was the hospital 
that utilized drugs the most. This was consistent with antidiabetics expenditures at 
the different hospitals Of combination therapies in use, rapid-acting and intermedi-
ate-acting insulin combination was increasingly the most utilized. cOnclusiOns: 
Expenditure trends are considerably over the increasing utilization and population 
trends, possibly indicating that the cost of drugs is not a priority consideration in 
drug selection and formulary inclusion at HMC.
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Objectives: Management of A1c (A), blood pressure (B) and cholesterol (C) levels 
is essential to reduce the risk of diabetic complications. In the past two decades, 
the results of landmark trials have led to increasingly aggressive treatment regi-
mens and thus more intensive use of glucose-lowering, anti-hypertensive and lipid-
lowering medications for patients. We examined the trends of the use and cost 
of the three types of drugs among diabetes patients in the U.S. between 1987 and 
2010. MethOds: Using the 1987 National Medical Expenditure Survey (n= 22538), 
and the Medical Expenditure Panel Survey in years 1997-98 (n= 57652) and 2009-10 
(n= 44815), we estimated the utilization and expenditures of ABC-control-related 
prescription medications among self-reported diabetes patients at the 3 time points. 
Within each drug type, usage was measured by the number of medication classes 
patients received, the share of each class and the total number of prescription 
medication encounters. Cost was measured by the payments from all payers, and 
presented in 2012 dollars. Results: Between 1987 and 2010, the number of glucose-
lowering encounters per patient nearly doubled. Patients used more varied classes. 
Usage of insulins and sulfonylureas declined from 38.7% and 67% to 29.9% and 35% 
respectively; Usage of initially unavailable medication classes – metformin, thia-
zolidinediones and DPP-4 inhibitors – increased to 59.2%, 14.5% and 9.5%, respec-
tively, in 2010. The patients that received ≥ 2 classes of glucose-lowering medications 
increased from 6% to 44%. Similar trends were observed for the other two drug 
types. The annual medical spending on glucose-lowering, anti-hypertensive and 
lipid-lowering drugs increased from $131 to $1,009, $62 to $647 and $146 to $449, 
respectively. cOnclusiOns: Usage and cost of medications for ABC control among 
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driven by declined annual family income ($56,139 in 2007 to $52,811 in 2010). This 
increasing trend was observed particularly among diabetic patients with low family 
income (2.3% in 2007 to 5.0% in 2010). In the contrast, the financial burden of medica-
tions was relieved for those aged younger than 18 years old (1.8% in 2007 to 0.3% in 
2010). Patients receiving insulins and thiazolidinediones had higher out-of-pocket 
spending as well as financial burden than those used other medications to treat 
diabetes. cOnclusiOns: Patients’ drug costs were reduced successfully between 
2007 and 2010. However, the financial burden of prescription drugs for diabetes 
increased due to decreased family income. Since the use of prescription drugs is a 
vital part of diabetes management, more efforts should be directed to patients with 
low family income in order to improve affordability of prescription drugs.
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Objectives: To examine the relative contribution of predisposing, enabling, need, 
and external environment factors to the excess health care expenditures associ-
ated with thyroid disorders among individuals with diabetes, compared to indi-
viduals with diabetes and without thyroid disorders. MethOds: Cross-sectional 
study design with data on adults over 20 years of age with diabetes (N = 4,920) from 
two years (2009 and 2011) of the Medical Expenditure Panel Survey (MEPS) were 
used. Ordinary least square regressions on log-transformed total expenditures 
were performed to estimate the excess expenditures associated with thyroid dis-
orders after controlling for predisposing, enabling, external environment, life-style 
and need factors as defined framework of the Anderson Behavior and Healthcare 
Utilization Model. Post-regression Blinder-Oaxaca (BO) decomposition analysis was 
performed to examine the relative contribution of factors in explaining the average 
differences in health care expenditures between the two groups. Results: Among 
individuals with diabetes, those with thyroid disorders had greater annual mean 
expenditure compared to those without thyroid disorders ($ 14,289 vs. $10,636, p < 
0.001). After accounting for the predisposing, enabling, external environment, life-
style and need factors, those with thyroid disorders had 15% greater health care 
expenditures compared to those without thyroid disorders. The BO decomposition 
analysis revealed that predisposing, enabling, external environment, life-style and 
need factors explained 63% of the excess health care expenditures among indi-
viduals with thyroid disorders. The excess health care expenditures between the 
groups was predominantly explained by need-factors (43%). Presence of cardiovas-
cular diseases, depression, arthritis, and cancer explained the excess expenditures 
between the groups among the need-factors. cOnclusiOns: Presence of thyroid 
disorders is associated with greater health care expenditures among individuals 
with diabetes. Co-management of co-occurring conditions may reduce the excess 
health care expenditures among individuals with thyroid disorders and diabetes.
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Objectives: To compare the burden of disease attributable to diabetes expressed in 
Disability Adjusted Life Years (DALYs) for five European countries in 2010. MethOds: 
DALYs lost to diabetes as the sum of years of life lost and years lived with disability 
were estimated by gender and age using country-specific epidemiological data and 
global disability weights. Data from various secondary sources were combined to 
estimate health loss due to diabetes for France, Germany, Italy, Spain and the UK. 
National statistical databases were used and in case necessary, community studies 
were used to derive the prevalence of diabetes by gender and age group which were 
weighted proportionately for a national population burden of disease estimate. All 
identified data were adapted to the Global Burden of Disease methodology (2010) 
to calculate the burden attributable to diabetes. No age weighting and discounting 
was applied. Sensitivity to different sources of variation was examined. Results: 
Germany and Italy lost the largest number of DALYs due to diabetes with 5.9 and 5.8 
per 1,000 inhabitants respectively, followed by Spain (4.4), France (3.7) and the UK 
(2.9). The highest burden was caused by mortality due to diabetes, with the excep-
tion of the UK, for which the burden due to disability of diabetes was higher. This 
may be explained by the way of reporting death in the UK. Mean DALYs lost were 
higher for women in Germany, Italy and Spain and showed to increase with age for 
all countries. Sensitivity analysis in variation in disability weights and uncertainty 
in epidemiological data showed to have effects on DALYs lost. cOnclusiOns: In 
spite of data limitations, the estimates reported here show that DALY loss due to 
diabetes imposes a substantial burden on countries. Cross-national variation in 
disease epidemiology was the largest source of variation in the burden of diabetes 
between countries.
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Objectives: Alogliptin-pioglitazone (alo-pio) reduces HbA1c levels in treatment-
naïve Type 2 diabetic (T2DM) patients, or those inadequately controlled by mon-
otherapy. Yet, the percentage of patients on alo-pio continuing to meet HbA1c 
thresholds suggested by the National Committee for Quality Assurance (NCQA) 
is unclear but may be important to accountable care organizations (ACOs). This 
analysis examined whether NCQA recognition, aligning with > 40% of patients 
below 7%, > 60% below 8%, and ≤ 15% above 9% HbA1c, is achievable. MethOds: 
ied across GLP-1RAs and analyses (ranging from 2.162 [p< 0.001] for exenatide vs. 
exenatide QW among initial adherers, to 0.986 [p= 0.798] for liraglutide 1.8mg vs. 
exenatide QW among initial adherers, to 0.869 [p< 0.001] for liraglutide 1.8mg vs. 
exenatide QW among all patients). cOnclusiOns: Among patients newly initiat-
ing exenatide QW, exenatide, or liraglutide, adherence was consistently highest for 
exenatide QW, while non-persistence varied by analyzed group.
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Objectives: The personal and economic burden of diabetes is substantial and 
growing in Japan due to its aging population. This study aimed to review the avail-
able literature on the usual treatment of adults with type 2 diabetes (T2DM) in 
Japan. MethOds: Systematic search of the scientific literature was performed on 
MEDLINE and EMBASE databases to identify publications about usual care of dia-
betes in Japan written in English or Japanese and published between January 2000 
and May 2013. Included keywords were diabetes mellitus, drug therapy and Japan. 
Randomized clinical trials, comparative or interventional studies were excluded. 
Of 17 publications that met search criteria, 13 pertained to adults with T2DM, of 
which 9 contained original survey data and 4 were literature reviews. Results: 
Almost all of the available data was at least 7 years old. Based on data from 2000 to 
2002, the use of oral anti-diabetic drugs (OAD) alone was the most prevalent treat-
ment option (51.4%), followed by diet alone (25.4%), insulin alone (15.4%), and OAD 
with insulin (7.8%). Although overall, sulfonylureas was the preferred class of OAD 
(61-67%), its use among treatment initiators has dramatically declined from 40% to 
22% following the introduction of dipeptidyl peptidase-4 inhibitors (DPP4) in 2009. 
Since then, the prescription rate of DPP4 increased to nearly 40% due to its perceived 
better safety. cOnclusiOns: Available data on the treatment of diabetes in usual 
care in Japan is rather sparse and not recent. Results indicate that the treatment 
of adults with T2DM in Japan with OAD and insulin is rather similar to that in the 
US and Europe, although the specific OAD in Japan is different. Further research is 
needed on the usual treatment of diabetes in Japan, considering increased longev-
ity, lifestyle changes, ongoing introduction of new medications, changes in disease 
management practices and increased economic concerns.
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Objectives: Type II Diabetes Mellitus (DM) is exponentially growing in Chile. A 
recent reform aimed at reducing inequities in health care in the country, but the 
gap between social groups continues to grow. We aimed at exploring the exist-
ence of under-diagnosis of type II DM in adult population in Chile. MethOds: 
Secondary analysis of cross-sectional Chilean Health Survey 2009-2010 (n= 4767 
adults, weighted sample: 13,347,316). We compared the proportion of adult popula-
tion self-reporting type II DM against the proportion with altered fasting glycae-
mia (value > 126mg/dl, Chi-square test) and then assessed the socio-demographic 
characteristics of those having the condition but ignoring it. For population-rep-
resentative analysis we used Stata 12.0. Results: 48.7% sample were men, mean 
age was 42 years (s.d.:40.8), 56.9% had middle socioeconomic status (SES), followed 
by high and low (18.6%, 24.5%) and 87% lived in urban areas. A 7.8% reported being 
diagnosed with type II DM. There was a significantly higher rate of self-reported 
DM among women than men (5.0% versus 2.8%) and people living in urban versus 
rural settings (6.7% and 1.0%). People with self-reported DM were on average 17 
years older than people without previous diagnosis (mean:57.1). According to lab 
results, 8.4% of the total adult population had type II DM. From this group, over half 
(4.6%) had not been diagnosed with this condition before, representing over 280,000 
people. They are mostly middle-aged men (mean age:46.6) from low and middle SES 
and living in urban areas. cOnclusiOns: We found an under-diagnosis of type II 
DM among middle-aged male adults in Chile. Few recent studies report the urgent 
need to develop community-based strategies to enhance male use of health care, 
particularly to pursue screening consultations even when feeling healthy. This study 
supports such initiative and challenges the complex relationship between gender 
and SES, which could be further explored in Chile.
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Objectives: To examine the changes in out-of-pocket spending and financial 
burden of prescription drugs for diabetes between 2007 and 2010. MethOds: The 
Medical Expenditure Panel Survey for 2007-2010 was analyzed for patients with 
diabetes. Out-of-pocket spending was defined as any self-reported coinsurance and 
deductibles, as well as payments for prescription medications that were not covered 
by insurance. Financial burden for prescription drugs was measured using the pro-
portion of out-of-pocket expenditures divided by total family income in a given year. 
Expenditures for each year were adjusted using Consumer Price Index. Results: 
The out-of-pocket spending for prescription drugs for treating diabetes was dropped 
significantly from $232.5 in 2007 to $197.9 in 2010, while the total expenditure for 
prescription drugs for diabetes increased dramatically from $875.9 to $1026.3 dur-
ing the same period. This declined out-of-pocket spending was observed across 
different age, gender, and racial groups. From 2007 to 2010, the financial burden 
of prescriptions drugs for diabetes increased from 0.8% to 1.1%, which was largely 
